X4 Pharmaceuticals (XFOR)
(Delayed Data from NSDQ)
$1.17 USD
+0.04 (3.10%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.18 +0.02 (1.29%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
XFOR 1.17 +0.04(3.10%)
Will XFOR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for XFOR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XFOR
What Makes X4 Pharmaceuticals (XFOR) a New Buy Stock
All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy
XFOR: What are Zacks experts saying now?
Zacks Private Portfolio Services
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Misses Revenue Estimates
Other News for XFOR
12 Health Care Stocks Moving In Friday's Intraday Session
Biotech Alert: Searches spiking for these stocks today
Catalyst Watch: Apple earnings, Viking IPO, Chinese EV deliveries and Russell indices' Rank Day
X4 Pharmaceuticals: PDUFA Excitement Ahead
Commit To Buy X4 Pharmaceuticals At $1, Earn 48.2% Annualized Using Options